Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

BACKGROUND: A substantial change in trial methodology for solid tumours has taken place, in response to increased understanding of cancer biology. FOCUS4 is a phase 2–3 trial programme testing targeted agents in patients with advanced colorectal cancer in molecularly stratified cohorts. Here, we aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, Richard, Brown, Ewan, Brown, Louise, Butler, Rachel, Falk, Stephen, Fisher, David, Kaplan, Richard, Quirke, Phil, Richman, Susan, Samuel, Leslie, Seligmann, Jenny, Seymour, Matt, Shiu, Kai Keen, Wasan, Harpreet, Wilson, Richard, Maughan, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125825/
https://www.ncbi.nlm.nih.gov/pubmed/29254887
http://dx.doi.org/10.1016/S2468-1253(17)30394-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125825/
https://www.ncbi.nlm.nih.gov/pubmed/29254887
http://dx.doi.org/10.1016/S2468-1253(17)30394-1

Ejemplares similares